Acknowledgement
The author wishes to thank Ms. Michael G. Stabin from Department of Radiology and Radiological Sciences, Vanderbilt University, fur supplying the S-values for lutetium-177 radionuclide.
References
- A. Bahrami-Samani, R. Bagheri, A.R. Jalilian, S. Shirvani-Arani, M. Ghannadi-Maragheh, M. Shamsaee, Production, quality control and pharmacokinetic studies of 166Ho-EDTMP for therapeutic applications, Sci. Pharm. 78 (2010) 423-433. https://doi.org/10.3797/scipharm.1004-21
- S. Dalvand, M. Sadeghi, Bone marrow dosimetry for 141Ce-EDTMP as a potential bone pain palliation complex: a Monte Carlo study, Appl. Radiat. Isot. 182 (2022), 110113.
- Z. Bayat, E. Saeedzadeh, N. Vahidfar, M. Sadeghi, et al., Preparation and validation of [67Ga]Ga-phytate kit and Monte Carlo dosimetry: an effort toward developing an impressive lymphoscintigraphy tracer, J. Radioanal. Nucl. Chem. 331 (2022) 691-700. https://doi.org/10.1007/s10967-021-08183-z
- R. Bagheri, A.R. Jalilian, A. Bahrami-Samani, M. Mazidi, M. Ghannadi-Maragheh, Production of Holmium-166 DOTMP: a promising agent for bone marrow ablation in hematologic malignancies, Iran J. Nucl. Med. 19 (2011) 12-20.
- S.A. Sahafi-Pour, S.P. Shirmardi, E. Saeedzadeh, S. Baradaran, M. Sadeghi, Internal dosimetry studies of 177Lu-BBN-GABA-DOTA, as a cancer therapy agent, in human tissues based on animal data, Appl. Radiat. Isot. 186 (2022), 110273.
- F. Johari Daha, M. Shafiei, Sh. Sheibani, et al., Production of 177Lu and formulation of Ethylene diamine tetramethylene phosphonate (EDTMP) kits as a bone-seeking radiopharmaceutical, Iran, J. Radiat. Res. 7 (2010) 229-234.
- M. Tomblyn, The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases, Cancer Control. 19 (2012) 137-144. https://doi.org/10.1177/107327481201900208
- S.P. Shirmardi, E. Saniei, T. Das, M. Noorvand, et al., Internal dosimetry studies of 170Tm-EDTMP complex, as a bone pain palliation agent, in human tissues based on animal data, Appl. Radiat. Isot. 166 (2020), 109396.
- IAEA, Therapeutic Applications of Radiopharmaceuticals, IAEA, Vienna, 2001. TECDOC-1228.
- R. Bagheri, H. Afarideh, M. Ghannadi-Maragheh, A. Bahrami-Samani, S.P. Shirmardi, Dosimetric study of radium-223 chloride and 153Sm-EDTMP for treatment of bone metastases using MCNPX code and available experimental data, J. Radioanal. Nucl. Chem. 303 (2015) 1991-1998.
- S. Nilsson, R.H. Larsen, S.D. Fossa, et al., First clinical experience with a-emitting radium-223 in the treatment of skeletal metastases, Clin. Cancer Res. 11 (2005) 4451-4459. https://doi.org/10.1158/1078-0432.CCR-04-2244
- T. Das, S. Chakraborty, P.R. Unni, S. Banerjee, G. Samuel, H.D. Sarma, M. Venkatesh, M.R.A. Pillai, 177Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation, Appl. Radiat. Isot. 57 (2002) 177-184. https://doi.org/10.1016/S0969-8043(02)00104-5
- S. Chakraborty, T. Das, P.R. Unni, H.D. Sarma, G. Samuel, S. Banerjee, M. Venkatesh, N. Ramamoorthy, M.R.A. Pillai, 177Lu labelled polyaminophosphonates as potential agents for bone pain palliation, Nucl. Med. Commun. 23 (2002) 67-74. https://doi.org/10.1097/00006231-200201000-00011
- I.A. Abbasi, Preliminary studies on 177Lu-labeled sodium pyrophosphate (177Lu-PYP) as a potential bone-seeking radiopharmaceutical for bone pain palliation, Nucl. Med. Biol. 39 (2012) 763-769. https://doi.org/10.1016/j.nucmedbio.2012.02.001
- I.A. Abbasi, Studies on 177Lu-labeled methylene diphosphonate as potential bone-seeking radiopharmaceutical for bone pain palliation, Nucl. Med. Biol. 38 (2011) 417-425. https://doi.org/10.1016/j.nucmedbio.2010.09.013
- M.P. Yadav, S. Ballal, M. Meckel, F. Roesch, C. Bal, [177Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety results, EJNMMI Res. 10 (2020) 1-13. https://doi.org/10.1186/s13550-019-0588-4
- S. Chakraborty, T. Das, H.D. Sarma, M. Venkatesh, S. Banerjee, Comparative studies of 177Lu-EDTMP and 177Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis, Appl. Radiat. Isot. 66 (2008) 1196-1205. https://doi.org/10.1016/j.apradiso.2008.02.061
- T. Das, S. Chakraborty, H.D. Sarma, S. Banerjee, 177Lu-DOTMP: a viable agent for palliative radiotherapy of painful bone metastasis, Radiochim. Acta 96 (2008) 55-61. https://doi.org/10.1524/ract.2008.1464
- N. Bollampally, J. Shukla, B.R. Mittal, et al., Efficacy and safety of 177Lu-DOTMP in palliative treatment of symptomatic skeletal metastases: a prospective study, Nucl. Med. Commun. 42 (2021) 964-971. https://doi.org/10.1097/MNM.0000000000001425
- A. Bahrami-Samani, A. Anvari, A.R. Jalilian, et al., Production, quality control and pharmacokinetic studies of 177Lu-EDTMP for human bone pain palliation therapy trials, Iran, J. Pharm. Sci. 11 (2012) 137-144.
- J. Yuan, C. Liu, X. Liu, et al., Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer, Clin. Nucl. Med. 38 (2013) 88-92. https://doi.org/10.1097/RLU.0b013e318279bf4d
- A.S. Shinto, D. Shibu, K.K. Kamaleshwaran, et al., 177Lu-EDTMP for treatment of bone pain in patients with disseminated skeletal metastases, J. Nucl. Med. Technol. 42 (2014) 55-61. https://doi.org/10.2967/jnmt.113.132266
- M. Alavi, Sh. Omidvari, A. Mehdizadeh, A.R. Jalilian, A. Bahrami-Samani, Metastatic bone pain palliation using 177Lu-Ethylenediaminetetramethylene phosphonic acid, World J. Nucl. Med. 14 (2015) 109-115. https://doi.org/10.4103/1450-1147.157124
- K.K. Agarwal, S. Singla, G. Arora, C. Bal, 177Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study, Eur. J. Nucl. Med. Mol. Imaging 42 (2015) 79-88. https://doi.org/10.1007/s00259-014-2862-z
- C. Bal, G. Arora, P. Kumar, et al., Pharmacokinetic, dosimetry and toxicity study of 177Lu-EDTMP in patients: phase 0/I study, Curr. Radiopharm. 9 (2016) 71-84. https://doi.org/10.2174/1874471008666150313105000
- H. Balter, T. Victoria, T. Mariella, 177Lu-labeled agents for neuroendocrine tumor therapy and bone pain palliation in Uruguay, Curr. Radiopharm. 9 (2016) 85-93. https://doi.org/10.2174/1874471008666150313112620
- S. Sharma, B. Singh, A. Koul, B.R. Mittal, Comparative therapeutic efficacy of 153Sm-EDTMP and 177Lu-EDTMP for bone pain palliation in patients with skeletal metastases: patients' pain score analysis and personalized dosimetry, Front. Med. 4 (2017) 1-9.
- T. Das, S. Banerjee, Theranostic applications of lutetium-177 in radionuclide therapy, Curr. Radiopharm. 9 (2016) 94-101. https://doi.org/10.2174/1874471008666150313114644
- M. Mirkovic, Z. Milanovic, D. Stankovic, et al., Investigation of 177Lu-labeled HEDP, DPD, and IDP as potential bone pain palliation agents, J. Radiat. Res. Appl. Sci. 13 (2020) 27-36.
- J. Zaknun, C. Bal, P. Dupont, Pharmacokinetics and dosimetry of the bone-seeking agent 177Lu-EDTMP in patients with metastatic prostate cancer, J. Nucl. Med. 52 suppl1 (2011) 1748.
- S. Chakraborty, T. Das, Sh. Banerjee, et al., 177Lu-EDTMP: a viable bone pain palliative in skeletal metastasis, Cancer Biother. Radiopharm. 23 (2008) 202-213.
- M.J. Belanger, S.M. Krause, C. Ryan, S. Sanabria-Bohorquez, W. Li, T.G. Hamill, et al., Biodistribution and radiation dosimetry of 18F-PEB in nonhuman primates, Nucl. Med. Commun. 29 (2008) 915-919. https://doi.org/10.1097/MNM.0b013e3283060c72
- W.K.A. Louw, C. Domehl, A.J. van Rensburg, N. Hugo, A.S. Alberts, O.E. Forsyth, et al., Evaluation of samarium-153 and holmium-166-EDTMP in the normal baboon model, Nucl. Med. Biol. 23 (1996) 935-940. https://doi.org/10.1016/S0969-8051(96)00117-5
- W.E. Bolch, K.F. Eckerman, G. Sgouros, S.R. Thomas, MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry-standardization of nomenclature, J. Nucl. Med. 50 (2009) 477-484. https://doi.org/10.2967/jnumed.108.056036
- J.A. Siegel, Establishing a clinically meaningful predictive model of hematologic toxicity in nonmyeloablative targeted radiotherapy: practical aspects and limitations of red marrow dosimetry, Cancer Biother. Radiopharm. 20 (2005) 126-140.
- R.B. Sparks, B. Aydogan, Comparison of the effectiveness of some common animal data scaling techniques in estimating human radiation dose, in: Proceedings of the Sixth International Radiopharmaceutical Dosimetry Symposium, Oak Ridge Associated Universities, Oak Ridge, TN, 1996, pp. 705-716.
- ICRP, ICRP Publication 23, Report of the Task Group on Reference Man, Pergamon Press, New York, 1975.
- J.M. Peters, E.M. Boyd, Organ weights and water levels of the rat following reduced food intake, J. Nutr. 90 (1966) 354-360. https://doi.org/10.1093/jn/90.4.354
- G. Miller, J.A. Klumpp, D. Poudel, W. Weber, R.A. Guilmette, J. Swanson, Americium systemic biokinetic model for rats, Radiat. Res. 192 (2019) 75-91. https://doi.org/10.1667/RR15256.1
- M.G. Stabin, R.B. Sparks, E. Crowe, OLINDA/EXM: the Second-generation personal computer software for internal dose assessment in nuclear medicine, J. Nucl. Med. 46 (2005) 1023-1027.
- ICRP, ICRP Publication 103, the 2007 Recommendations of the International Commission on Radiological Protection, ume 37, Elsevier, 2007.
- R. Bagheri, H. Afarideh, M. Ghannadi-Maragheh, S.P. Shirmardi, A. Bahrami-Samani, Study of bone surface absorbed dose in treatment of bone metastases via selected radiopharmaceuticals: using MCNP4C code and available experimental data, Cancer Biother. Radiopharm. 30 (2015) 174-181.
- R. Bagheri, A. Bahrami-Samani, M. Ghannadi-Maragheh, Estimation of radiation absorbed dose in man from 166Ho-EDTMP based on biodistribution data in Wistar rats, Radiat. Phys. Chem. 187 (2021) 1-6. https://doi.org/10.1016/j.radphyschem.2021.109560
- ICRP, ICRP Publication 89, Basic Anatomical and Physiological Data for Use in Radiological Protection: Reference Values, Pergamon Press, New York, 2002.
- M.L. Barlett, M. Webb, S. Durrant, A.J. Morton, R. Allison, D.J. Macfarlene, Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other hematological malignancies, Eur. J. Nucl. Med. 29 (2002) 1470-1477. https://doi.org/10.1007/s00259-002-0934-y
- H.B. Breitz, R.E. Wendt III, M.S. Stabin, S. Shen, W.D. Erwin, J.G. Rajendran, et al., 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy, J. Nucl. Med. 47 (2006) 534-542.
- F. Rosch, H. Herzog, C. Plag, B. Neumaier, U. Braun, H.W. Muller-Gartner, et al., Radiation doses of yttrium-90 citrate and yttrium-90 EDTMP as determined via analogous yttrium-86 complexes and positron emission tomography, Eur. J. Nucl. Med. 23 (1996) 958-966. https://doi.org/10.1007/BF01084371
- L. Vigna, R. Matheoud, S. Ridone, D. Arginelli, P. Della Monica, M. Rudoni, et al., Characterization of the [153Sm]Sm-EDTMP pharmacokinetics and estimation of radiation absorbed dose on an individual basis, Phys. Med. 27 (2011) 144-152. https://doi.org/10.1016/j.ejmp.2010.08.001
- M. Lyra, G. Papanikolos, P. Phinou, A.P. Frantzis, J. Jordanou, G.S. Limouris, Rhenium-186-HEDP dosimetry and multiple bone metastases palliation therapy effects, Radionuclide Ther. Oncol. Curr. Status Future Aspects 10 (2003) 51-60.
- K. Liepe, R. Hliscs, J. Kropp, R. Runge, F.F. Knapp Jr., W.G. Franke, et al., Dosimetry of 188Re-Hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases, J. Nucl. Med. 44 (2003) 953-960.